BIOMUNEX discovers and develops new treatments based on disruptive data driven biological approaches in immuno-oncology for patients with unmet medical needs, using the bi- and multi-specific antibody technology BiXAb®. Our flagship program uses our BiXAb® antibody platform to redirect a unique, non-conventional T-Cell (ncTC) sub-population to specifically engage and kill cancer cells and overcome some of the limitations of classical T-cell engagers. The BMX-500 program of BIOMUNEX, in collaboration with the “Cancer and Immunity” Unit at the Curie Institute led by Dr. Amigorena, focuses on developing novel disruptive and potentially universal T cell redirection approach. This innovative approach aims to overcome some of the limitations of current CD3-based T cell redirecting therapeutic strategies, such as cytokine release storm and dose-limiting toxicity. This novel strategy may result in a major advancement in the immunotherapy of cancers for both solid tumors and hematological malignancies. BMX-101 targets CD38 & PD-L1 and is expected to elicit anti-CD38 cytotoxic activity, while simultaneously activating the immune system by blocking PD-L1, an immune checkpoint, at the site of the tumor, thereby increasing the therapeutic index and efficacy in patients. In 2018, the Nobel prize for Medicine was awarded to an approach based on antibodies that blocked the PDL1/PD1 immune checkpoint axis and attenuation of this checkpoint continues to yield positive clinical responses, as judged the regular updates presented at the ASCO congress (American Society of Clinical Oncology) and many others. BMX-101 is on schedule to soon be in clinical development for the treatment of hematological malignancies. Other ongoing development candidates target members of the EGFR receptor family. The BMX-002 BiXAb® drug candidate was notably used for validation of the BiXAb® platform technology, demonstrating a superior efficacy versus the combination of the parental monoclonal antibodies. BMX-002 was evaluated in several preclinical models and demonstrated the POC for the synergistic targeting of EGFR and HER2 in solid tumors. BMX-101, BMX-002 programs and other ongoing programs, have demonstrated the superior value of the BiXAb® technology: rapid production, quick generation of the IP covering the molecule, excellent drug like properties, manufacturability and COGS (Cost of Goods Sold), and finally versatility and multi-specific capabilities. They are expected to bring disruptive biological approaches (e.g., non-conventional T Cell redirection platform). Other BIOMUNEX programs include development of novel double immune checkpoint inhibitors and tri-specific antibodies. BIOMUNEX is also evaluating other discovery programs focused on innovative targets or pairs of targets that should become breakthrough immunotherapies in the future. Several patent family applications have been filed to protect such disruptive approaches.